We are live on
!
Find out more
PSC
Patient Square Capital Portfolio holdings
AUM
$564M
1-Year Est. Return
261.3%
This Fund
S&P 500
This Quarter
Est. Return
+24.72%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$205M
AUM Growth
+$81M
(+65%)
Cap. Flow
+$52M
Cap. Flow
% of AUM
25.32%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$52M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
TCP
AHSW
KF
KBG
AAS
LC
AMCA
OC
Patient Square Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Patient Square Capital held 2 positions worth $205M, up 65% from $124M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Patient Square Capital deployed $52M of net new capital in Q2 2023, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Patient Square Capital added most to Roivant Sciences in Q2 2023, an estimated $52M increase.
- Patient Square Capital's ten largest holdings make up 100% of its $205M portfolio in Q2 2023.
- Patient Square Capital opened 0 new positions and closed 0 in Q2 2023.
- Patient Square Capital's portfolio value rose 65% quarter-over-quarter to $205M.
Based on Patient Square Capital's 13F filing for Q2 2023, filed 11 Aug 2023.